China’s first CAR-T Cell Therapy approved-Fosun Kite Axicabtagene Ciloleucel (FKC876)

0
20
  • The first* CAR-T cell therapy approved by NMPA: opening a new era of cell therapy in China
  • Individualized living-cell-based medicine: genetically modify patient’s T-cells to expresses a chimeric antigen receptor (CAR) that will activate T-cells upon engaging cells carrying the specific antigen and conduct targeting 
  • The bridging trial results has demonstrated remarkable similarity between Axicabtagene Ciloleucel (FKC876) and Yescarta® in terms of efficacy and safety both in U.S. clinical and real-world setting[1]

SHANGHAI, June 24, 2021 /PRNewswire/ — On June 23, 2021, Fosun Kite Biotechnology announced its autologous CD19-directed CAR-T cell therapy Axicabtagene Ciloleucel (FKC876) (axicabtagene ciloleucel) has been approved by China National Medical Products Administration (NMPA) for the treatment of adult patients with relapsed or refractory large B-cell lymphoma (r/r LBCL) after two or more lines of systemic therapy, including diffuse…

Read more…